Tirzepatide (Mounjaro, Zepbound, compounded) Tirzepatide is a dual GIP/GLP-1 agonist, meaning it activates two receptor types instead of one
From six months to one year of use, the percent of patients who experienced at least 75% of repigmentation on their face increased from 30% to nearly 50%
Since then, more than ten types of GLP-1 receptor agonists have received FDA approval and been brought to market, and with each new version, their effectiveness has increased
Peptides have become increasingly popular in recent years, driven by the stratospheric rise of injectable GLP-1s for weight loss and a fleet of gray market peptides claiming to help with post-workout recovery, hormone balance, hair loss, and skin health
Hopefully we've given them a guide to the here-and-now